AI Convergence: Small Molecule Discovery Summit

AI Convergence: Small Molecule Discovery Summit is organized by Hanson Wade and will be held from Mar 18 - 20, 2026 at Homewood Suites by Hilton Boston Seaport District, Boston, Massachusetts, United States of America.

Description:
Cutting-edge AI/ML-driven breakthroughs, including Monte Rosa Therapeutics’ progress in molecular glue degraders, Insilico Medicine’s recent deal with Eli Lilly, the launch of Eli Lilly's TuneLab, coupled with ongoing partnerships between Merck and Variational AI, and Pfizer and XtalPi, are fueling accelerated small molecule innovation. Biopharma are actively pursuing, and investing in, AI/ML approaches that integrate computational and medicinal chemistry insights to re-architect the small molecule discovery funnel.

The inaugural AI Convergence: Small Molecule Discovery Summit arrives at this pivotal juncture to immerse you in the applied learnings needed to catalyze the next wave of AI/ML-powered small molecule development. Delve into AI/ML applications that elucidate undruggable target protein folding, supercharge structure- and ligand-based design, leverage AI/ML-enabled virtual screening to tap into unexplored chemical space, use generative molecular design for molecular glues, covalent inhibitors and degraders, optimize ADME-T, and address data input and federated learning platform opportunities.

Unite with industry leaders such as Insilico Medicine, Psivant Therapeutics, OpenADMET, Sanofi, Novo Nordisk, as well as newcomers including Eli Lilly’s TuneLab, Expedition Medicines and Montai Therapeutics. Expect to explore AI/ML methods, use cases and the convergence of state-of-the-art AI/ML tools, alongside existing approaches, to ignite future AI/ML-enabled small molecule discovery.

Speakers: Avner Schlessinger, Professor and Director - Pharmacology and Therapeutics Discovery Training Area, AI Small Molecule Drug Discovery Center, Icahn School of Medicine at Mount Sinai, Hariprasad Vankayalapati, Co-Founder and Chief Scientific Officer, Biolexis Therapeutics, Mauricio Cortes, Senior Director and Head, Discovery Science, Cellarity Therapeutics, Maximilian Ebert, Executive Director, Computational Molecular Sciences, Congruence Therapeutics, Ivan Cornella-Taracido, Chief Scientific Officer and Co-Founder, Covant Therapeutics, Henry van den Bedem, Chief Technology Officer, Expedition Medicines, Petrina Kamya, Vice President and Global Head, AI Platforms, Insilico Medicine, Daniel Haders, Chief Executive Officer, Model Medicines, Hok Hei Tam, Co-Founder, Chief Technology Officer and Senior Principal, Montai Therapeutics and Flagship Pioneering, Tom Shani, Co-Founder and Chief Executive Officer, Pro-Phet, Shivam Patel, Head, Data Sciences and ML, Psivant Therapeutics, Rick Ewing, Vice President and Head, Chemistry, Rapafusyn Pharmaceuticals, Ajay Yekkirala, Co-Founder, Senior Vice President and Head, Discovery and Development, Superluminal Medicines, Jacob Berlin, Chief Executive Officer, Terray Therapeutics, Handol Kim, Chief Executive Officer, Variational AI, Jonathan Gilbert, Senior Director, Ecosystem Growth - TuneLab, Eli Lilly, Carol Mulrooney, Senior Principal Scientist, Cheminformatics, GSK, Xinhao Li, Senior Scientist II, In Silico Discovery, Johnson and Johnson, Vinicius Oliveira, Senior Scientist, Computational Chemistry, Novo Nordisk, David Kombo, Principal Scientist II, Sanofi, Alexander Hillisch, Head, Digital Molecule Discovery and Executive Director, UCB